338 related articles for article (PubMed ID: 28122069)
1. Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris.
Feldmeyer L; Mylonas A; Demaria O; Mennella A; Yawalkar N; Laffitte E; Hohl D; Gilliet M; Conrad C
JAMA Dermatol; 2017 Apr; 153(4):304-308. PubMed ID: 28122069
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab treatment of pityriasis rubra pilaris: A report of five cases.
Napolitano M; Lembo L; Fania L; Abeni D; Didona D; Didona B
J Dermatol; 2018 Feb; 45(2):202-206. PubMed ID: 29080273
[TBL] [Abstract][Full Text] [Related]
3. Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40.
Matsuda T; Yamazaki F; Ueda-Hayakawa I; Kambe N; Okamoto H
J Dermatol; 2019 Jan; 46(1):70-72. PubMed ID: 30506728
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
Boudreaux BW; Pincelli TP; Bhullar PK; Patel MH; Brumfiel CM; Li X; Heckman MG; Pittelkow MR; Mangold AR; Sluzevich JC
Br J Dermatol; 2022 Nov; 187(5):650-658. PubMed ID: 35701384
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.
Haynes D; Strunck JL; Topham CA; Ortega-Loayza AG; Kent G; Cassidy PB; Hu R; Choate K; Wang Z; Liu Y; Greiling TM
JAMA Dermatol; 2020 Jun; 156(6):668-675. PubMed ID: 32293641
[TBL] [Abstract][Full Text] [Related]
6. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation.
Maloney NJ; Hisaw LD; Worswick S
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 29034547
[TBL] [Abstract][Full Text] [Related]
7. Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial.
Velasco RC; Shao C; Cutler B; Strunck J; Kent G; Cassidy PB; Choate K; Greiling TM
JAMA Dermatol; 2024 Jun; 160(6):641-645. PubMed ID: 38598229
[TBL] [Abstract][Full Text] [Related]
8. Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review.
Chandy RJ; Chokshi A; Tan I; Feldman SR
J Cutan Med Surg; 2024; 28(3):269-275. PubMed ID: 38549359
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
Arakawa A; Ruzicka T; Prinz JC
JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of a child's pityriasis rubra pilaris (PRP) with ustekinumab and acitretin.
Katharina M; Sylvia S; Matthias B; Ulrich M; Martin L
Pediatr Dermatol; 2022 Jul; 39(4):659-661. PubMed ID: 35859269
[TBL] [Abstract][Full Text] [Related]
11. CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris.
Craiglow BG; Boyden LM; Hu R; Virtanen M; Su J; Rodriguez G; McCarthy C; Luna P; Larralde M; Humphrey S; Holland KE; Hogeling M; Hidalgo-Matlock B; Ferrari B; Fernandez-Faith E; Drolet B; Cordoro KM; Bowcock AM; Antaya RJ; Ashack K; Ashack RJ; Lifton RP; Milstone LM; Paller AS; Choate KA
J Am Acad Dermatol; 2018 Sep; 79(3):487-494. PubMed ID: 29477734
[TBL] [Abstract][Full Text] [Related]
12. Refractory pityriasis rubra pilaris with good response after treatment with ustekinumab.
Aragón-Miguel R; Prieto-Barrios M; Calleja-Algarra A; Velasco-Tamariz V; Andres-Lencina JJ; Ortiz-Romero P; Monsálvez-Honrubia V
J Dtsch Dermatol Ges; 2018 Aug; 16(8):1022-1025. PubMed ID: 29947473
[No Abstract] [Full Text] [Related]
13. Erythrodermic pityriasis rubra pilaris managed at home: intensive community care followed by ustekinumab.
Ismail N; Callander J; Williams M; Anstey AV
Clin Exp Dermatol; 2018 Aug; 43(6):749-751. PubMed ID: 29779249
[No Abstract] [Full Text] [Related]
14. A case of resistant pityriasis ribra pilaris responsive to combination acitrentin and ustekinumab.
Cook E; Tran KW; Kollipara S; Tarbox M; Akin R
Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609453
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14.
Lwin SM; Hsu CK; Liu L; Huang HY; Levell NJ; McGrath JA
Br J Dermatol; 2018 Apr; 178(4):969-972. PubMed ID: 28301045
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris.
Bonomo L; Levitt JO
Cutis; 2018 May; 101(5):367-369. PubMed ID: 29894526
[TBL] [Abstract][Full Text] [Related]
17. Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy.
Zhang YH; Zhou Y; Ball N; Su MW; Xu JH; Zheng ZZ
J Cutan Med Surg; 2010; 14(4):185-8. PubMed ID: 20642989
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of infliximab in pityriasis rubra pilaris is associated with pro-inflammatory cytokine inhibition.
Adnot-Desanlis L; Antonicelli F; Tabary T; Bernard P; Reguiaï Z
Dermatology; 2013; 226(1):41-6. PubMed ID: 23548788
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab treatment in severe atopic dermatitis: Down-regulation of T-helper 2/22 expression.
Weiss D; Schaschinger M; Ristl R; Gruber R; Kopp T; Stingl G; Bangert C
J Am Acad Dermatol; 2017 Jan; 76(1):91-97.e3. PubMed ID: 27745907
[TBL] [Abstract][Full Text] [Related]
20. Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials.
Siebert S; Sweet K; Dasgupta B; Campbell K; McInnes IB; Loza MJ
Arthritis Rheumatol; 2019 Oct; 71(10):1660-1669. PubMed ID: 31070869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
